Drug Profile


Alternative Names: PR 934423

Latest Information Update: 08 Oct 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca R&D Charnwood
  • Class Acetamides; Antiepileptic drugs; Antiparkinsonians; Neuroprotectants; Small molecules
  • Mechanism of Action Glutamate receptor antagonists; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Epilepsy; Huntington's disease; Neurological disorders; Neuropathic pain; Parkinson's disease; Stroke

Most Recent Events

  • 25 Jul 2002 Discontinued - Clinical-Phase-Unknown for Neuropathic pain in USA (unspecified route)
  • 25 Jul 2002 Discontinued - Phase-II for Neurological disorders in USA (unspecified route)
  • 25 Jul 2002 Discontinued - Phase-II for Parkinson's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top